Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

ctDNA monitoring during EGFR-TKI treatment is useful for detecting T790M mutation. However, the efficacy of osimertinib treatment based on T790M status in plasma ctDNA remains to be established. Abstract Background Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kina...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2019-06, Vol.49 (6), p.554-558
Hauptverfasser:	Usui, Kazuhiro, Yokoyama, Takuma, Naka, Go, Ishida, Hiroo, Kishi, Kazuma, Uemura, Kohei, Ohashi, Yasuo, Kunitoh, Hideo
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Aniline Compounds Antineoplastic Agents - therapeutic use Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Circulating Tumor DNA - blood Disease Progression ErbB Receptors - genetics Female Humans Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Mutation - drug effects Neoplasm Recurrence, Local - drug therapy Original Piperazines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!